Atmo Biosciences appoints world-renowned gastroenterologist Professor Eamonn Quigley as Medical Advisory Board Chair
Posted: 1 May 2023 Atmo Biosciences, a company commercializing the world’s first ingestible gas-sensing capsule that provides insights into gut health and microbiome function, today announced the appointment of renowned gastroenterologist Professor Eamonn Quigley as Chair of its…
Cartherics grants Shunxi Licence for CAR-T Cell Therapy for Ovarian Cancer in Greater China
Posted: 1 May 2023 Cartherics Pty Ltd, a biotechnology company developing immune cell therapies for the treatment of cancer, announced today that it has granted Shunxi Holding Group Co Ltd (“Shunxi”) a licence to develop, manufacture and commercialise…
Immutep Receives Approval to Initiate INSIGHT-005 Trial Evaluating Eftilagimod Alpha and Anti-PD-L1 Therapy BAVENCIO
Posted: 1 May 2023 Immutep Limited, a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces it has received regulatory approval from the Paul-Ehrlich-Institut (“PEI”), German Federal Institute for Vaccines and Biomedicines, to…
Nominations are now open for the 2023 GSK Award for Research Excellence!
Posted: 27 April 2023 Closes: 16 June 2023 Nominations are now open for the 2023 GSK Award for Research Excellence! The GSK Award for Research Excellence (ARE) is one of the most prestigious and longstanding awards available to…
Cytiva supports BioCina with first GMP production and development facility for mRNA in Australia
Posted: 27 April 2023 Cytiva and the University of Adelaide are collaborating with BioCina, an Australian-based multi-product biologics contract development and manufacturing organization (CDMO), to expand its facility in Adelaide to manufacture mRNA-based vaccines and therapies. Fellow Danaher…
Establishment of two sub-faculties within the Faculty of Medicine, Nursing and Health Sciences and appointment of sub-faculty deans
Posted: 27 April 2023 Monash University has announced the establishment of two new sub-faculties within the Faculty of Medicine, Nursing and Health Sciences (MNHS), the Sub-Faculty of Health Sciences and the Sub-Faculty of Clinical and Molecular Medicine. Professor…
Landmark Malawi trial boosts iron levels in pregnant women
Posted: 27 April 2023 The World Health Organization (WHO) currently recommends oral iron taken twice daily as the standard of care in developing nations, but adherence to this treatment is poor. The finding, driven by a collaboration between…
HER2-targeted DEP SN-38 ADC outperforms in HER2+ human cancer model
Posted: 26 April 2023 Starpharma today announces that it has developed a HER2-targeted DEP® SN-38 antibody-drug conjugate (ADC), which has shown significant anti-tumour activity in a HER2+ human ovarian cancer xenograft model, outperforming the approved ADC product, Enhertu®[2]. ADCs…
AZD0466 active in small cell lung cancer patient models
Posted: 21 April 2023 Starpharma announces AZD0466 results from a preclinical study in small cell lung cancer (SCLC) patient-derived xenograft (PDX) models. Starpharma’s partner, AstraZeneca, presented these results overnight at the American Association for Cancer Research (AACR) Annual Meeting.…
International partnership launches Monash University-Helmholtz lab to solve global oncology, cardiology and infectious disease challenges
Posted: 21 April 2023 Monash University has partnered with the Helmholtz-Zentrum Dresden-Rossendorf (HZDR), a member of the Helmholtz Association of German Research Centres to establish the Monash-Helmholtz Laboratory for Radio-Immuno-Theranostics (MHELTHERA) to enable clinical translation at a launch…
ANDHealth Partners with Chicago ARC to Bring Australian Digital Health Startups into the U.S. Market
Posted: 21 April 2023 Chicago ARC Executive Director Kate Merton and ANDHealth CEO and Managing Director Bronwyn Le Grice today announced an exciting new partnership to connect Australia’s best and brightest digital health companies with U.S. partners and…
DAYBUE (trofinetide) launched in US – Neuren earns US$40m
Posted: 19 April 2023 Neuren Pharmaceuticals reported that its North America partner Acadia Pharmaceuticals (NASDAQ: ACAD) has announced that DAYBUE™ (trofinetide) is now available for the treatment of Rett syndrome in adult and pediatric patients two years of…
